within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG05_Vedolizumab;

model Vedolizumab
  extends Pharmacolibrary.Drugs.ATC.L.L04AG05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AG05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin, thereby blocking the interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1). It is approved for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults, acting as a gut-selective anti-inflammatory agent.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters for vedolizumab in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.</p><h4>References</h4><ol><li><p>Feagan, BG, et al., &amp; Parikh, A (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>The New England journal of medicine</i> 369(8) 699–710. DOI:<a href=\"https://doi.org/10.1056/NEJMoa1215734\">10.1056/NEJMoa1215734</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23964932/\">https://pubmed.ncbi.nlm.nih.gov/23964932</a></p></li><li><p>Sandborn, WJ, et al., &amp; Vermeire, S (2020). Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> 158(3) 562–572.e12. DOI:<a href=\"https://doi.org/10.1053/j.gastro.2019.08.027\">10.1053/j.gastro.2019.08.027</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31470005/\">https://pubmed.ncbi.nlm.nih.gov/31470005</a></p></li><li><p>Hyams, JS, et al., &amp; Lirio, RA (2022). Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn&#x27;s Disease: Results from the Phase 2 HUBBLE Study. <i>Journal of Crohn&#x27;s &amp; colitis</i> 16(8) 1243–1254. DOI:<a href=\"https://doi.org/10.1093/ecco-jcc/jjac036\">10.1093/ecco-jcc/jjac036</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35301512/\">https://pubmed.ncbi.nlm.nih.gov/35301512</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Vedolizumab;
